On Friday, Catalyst Pharmaceuticals received an upgrade to its Relative Strength (RS) Rating, from 80 to 91.
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
History shows that the best-performing stocks often have an 80 or better RS Rating as they begin their largest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
The IBD 50 stock is trying to complete a consolidation with a 24.27 entry. See if it can break out in volume at least 40% above average.
Earnings growth decreased in the most recent report from 6% to 0%. But revenue moved higher, from 23% to 25%.
The company earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics and ADMA Biologics are also among the group's highest-rated stocks.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!